Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE ...Middle East

SUZHOU, China, and ROCKVILLE, Md., June 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE)...

Hence then, the article about global registrational phase iii study of olverembatinib for the treatment of patients with sdh deficient gist approved by the china cde was published today ( Tuesday 11/06/2024 - 05:56 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE )

Also on site :

• Soul Hitmaker Behind One of the ‘Greatest’ 1974 R&B Chart-Toppers “Let’s Straighten It Out,” Dies at 86
• MPs call for UK to hold Israeli government to account for killing of journalists following Independent investigation
• Hayden Panettiere Appeared ‘Beaten Up’ as Firefighters Transported Her on a Gurney 2 Years Before She Died: Neighbor